Woolley A, Golmard J-L, Kitchen S
Sheffield Haemophilia and Thrombosis Centre, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK.
Department de Biostatistiques, ER4/EA3974, Université Paris 6 et APHP, UF de biostatistique, GH Pitié-Salpêtrière, Paris, France.
Int J Lab Hematol. 2016 Aug;38(4):375-88. doi: 10.1111/ijlh.12498. Epub 2016 Jun 16.
Haemolysis, icterus and lipaemia (HIL) may affect haemostasis test results. This may be influenced by the level of interfering substance and the reagents and end-point detection system used.
We assessed the influence of HIL on prothrombin time, activated partial thromboplastin time and fibrinogen assay using a viscosity-based detection analyser.
Spontaneous haemolysis that occurred during sample collection and processing had no effect on PT with either a rabbit tissue factor extract or recombinant human tissue factor reagents. In contrast, addition of mechanically haemolysed cells impacted on PT for the highest haemoglobin concentration. For APTTs determined with STA®-Cephascreen® reagent, there was no significant difference between results in haemolysed and nonhaemolysed samples. For the other two reagents studied, APTTs were statistically significantly shorter in haemolysed samples compared with nonhaemolysed samples. This bias was clinically significant only for STA®-PTT Automate. For all three APTT reagents, the impact of haemolysis was sufficient to impact patient management decisions, and in some samples, the effects of lipaemia and icterus were not clinically significant.
Overall, our results confirm that PT and fibrinogen were not clinically significantly affected by HIL. The APTTs of some haemolysed samples were falsely normal. Haemolysed samples for APTT determination should be rejected.
溶血、黄疸和脂血(HIL)可能会影响止血测试结果。这可能受干扰物质水平以及所使用的试剂和终点检测系统的影响。
我们使用基于粘度的检测分析仪评估了HIL对凝血酶原时间、活化部分凝血活酶时间和纤维蛋白原测定的影响。
样本采集和处理过程中发生的自发性溶血对使用兔组织因子提取物或重组人组织因子试剂检测的凝血酶原时间没有影响。相比之下,添加机械溶血的细胞对血红蛋白浓度最高时的凝血酶原时间有影响。对于用STA®-Cephascreen®试剂测定的活化部分凝血活酶时间,溶血样本和未溶血样本的结果之间没有显著差异。对于所研究的其他两种试剂,与未溶血样本相比,溶血样本中的活化部分凝血活酶时间在统计学上显著缩短。这种偏差仅对STA®-PTT Automate具有临床意义。对于所有三种活化部分凝血活酶时间试剂,溶血的影响足以影响患者的管理决策,并且在一些样本中,脂血和黄疸的影响没有临床意义。
总体而言,我们的结果证实凝血酶原时间和纤维蛋白原在临床上没有受到HIL的显著影响。一些溶血样本的活化部分凝血活酶时间被错误地判定为正常。用于测定活化部分凝血活酶时间的溶血样本应被拒收。